Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review

  • Jaqueline Pinheiro de Alencar Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • Francisco Matheus Prado Luna Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • Matheus Barbosa Coelho Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • Raissa Maria Rolim Bem de Morais Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • José Antonio de Lima Neto Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil
  • Messias Silvano da Silva Filho Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil. Scholarship of Scientific Initiation, Brazil
  • Ivana Rios Rodrigues Department of Clinical Care Nursing and Health, Ceara State University - UECE, Fortaleza, Ceara, Brazil
  • Marcial Moreno Moreira Department of Health Sciences, Faculty of Medicine of ABC – FMABC, Santo André, São Paulo, Brazil
  • David de Sousa Gregório
  • Modesto Leite Rolim Neto Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil. Department of Medicine, Federal University of Cariri - Barbalha, Ceará, Brazil. Department of Health Sciences, Faculty of Medicine of ABC – FMABC, Santo André, São Paulo, Brazil.

Abstract

Background: The Irisin is a myokine associated with the improvement on insulin resistance caused by diet and increased physical energy expenditure. Recent studies have shown that patients with Type 2 Diabetes Mellitus (T2DM) have reduced levels of irisin, showing it as a potential marker for various endocrine and cardiovascular diseases. This study aimed to verify if T2DM patients never treated or without ongoing treatment have reduced levels of irisin when compared to individuals with other metabolic profiles.


Methods and Findings: Systematic review of the literature, considering the primary studies published in 2012 to 2016, with the outcome Irisin levels in patients never treated or without current treatment in the ambience of Type 2 Diabetes Mellitus. The search was conducted through the electronic database Scopus (Elsevier), using the key words: "Irisin", "Human" and "Diabetes Mellitus". From the 91 studies found, 8 met the eligibility criteria. Significant differences were found on levels of irisin in patients with T2DM compared to normoglycemic individuals, obese and/or pre-diabetic. On average, there was a reduction of 15 pg/ml in plasma levels of irisin in diabetics. However, a minority of studies says that this relationship does not exist.


Conclusion: Irisin reduced levels were found in patients with T2DM and is also related to lipid profile, with the risk of developing endocrine diseases, such as diabetes and obesity, and high risk for cardiovascular diseases because of its relationship with endothelial dysfunction. This generates the need for research in order to explore the isolation and clinical use of irisin for treatment of disorders related to imbalance in energy demand, obesity and diabetes.


Descriptors: Irisin, Human, Diabetes Mellitus.

Author Biography

Modesto Leite Rolim Neto, Department of Medicine, Estacio/FMJ - Juazeiro do Norte, Ceará, Brazil. Department of Medicine, Federal University of Cariri - Barbalha, Ceará, Brazil. Department of Health Sciences, Faculty of Medicine of ABC – FMABC, Santo André, São Paulo, Brazil.

References

The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes care. 1997;: p. 1183-97.

Shaw J, Sicree R, Zimmet P. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;: p. 4-14.

Ravussin E, Smith S. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation resul in ectopic fat storage, insulin resistance and type 2 diabetes mellitus. Ann N Y Acad Sci. 2002;: p. 363-7.

Esteve E, Ricart W, Fernández-Real J. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care. 2009.

Seale P, Conroe H, Estall J, Kajimura S, Frontin A, Ishibashi J, et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest. 2011;: p. 96-105.

Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Research. 2013;: p. 96-101.

Almind K, Manieri M, Sivitz W, Cinti S, Kahn C. Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proc Natl Acad Sci USA. 2007.

Lowell B, S-Susulic V, Hamann A, Lawitts J, Himms-Hagen J, Boyer B, et al. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature. 1993.

Yang X, Enerbäck S, Smith U. Reduced expression of FOXC2 and brown adipogenic genes in human subjects withinsulin resistance. Obes Res. 2003;: p. 1182–91.

Handschin C, Spiegelman BM. The role of exercise and PGC1α in inflammation and chronic disease. Nature. 2008 july 24;(454): p. 463-469.

Eckardt K, Görgens S, Raschke S, Eckel J. Myokines in insulin resistance and type 2 diabetes. Diabetologia. 2014;: p. 1087–99.

Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol. 2014;: p. 1091-1107.

Pedersen B, Febbraio M. Muscle as an endocrine organ: focus on muscle-derived interleukin–6. Physiol Rev. 2008;: p. 1379–1406.

Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1α-dependent myokine that drives browning of white fat and thermogenesis. Nature. 2012 January 26;(481): p. 463–468.

Bonfante ILP, Duft RG, Chacon-Mikahil MPT, Cavaglieri CR. New findings related to adipose tissue: review literature about browning and irisin. Arq. Ciênc. Saúde. 2015 abril-junho;: p. 9-15.

Liu J, Wong M, Toy W, Tan C, Liu S, Ng X, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. Journal of Diabetes and Its Complications. 2013 365–369;: p. 365–369.

Alis R, Sanchis-Gomar F, Pareja-Galeano H, Hernández-Mijares A, Romagnoli M, Víctor V, et al. Association between irisin and homocysteine in euglycemic and diabetic subjects. Clinical Biochemistry. 2014;: p. 333–335.

Espes D, Lau J, Carlsson P. Increased levels of irisin in people with long-standing Type 1 diabetes. Diabetic medicine. 2015.

Ebert T, Stepan H, Schrey S, Kralisch S, Hindricks J, Hopf L, et al. Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery. Cytokine. 2014.

Wang H, Zhang X, Chen W, Huang Q, Chen Q. Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes. Journal of Diabetes and Its Complications. 2014;: p. 384-389.

Xiang L, Xiang G, Yue L, Zhang J, Zhao L. Circulating irisin levels are positively associated with endotheliumdependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis. 2014;: p. 328-333.

Xie X, Gao T, Yang M, Chen P, Jin H, Yang L, et al. Associations of betatrophin levels with irisin in Chinese women with normal glucose tolerance. Diabetology & Metabolic Syndrome. 2015.

Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, García-Giménez J. Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes. 2012; 4: p. 196.

Moher D, Liberati A, Tetzlaff J, Altman D, Group. P. Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement. PLoS Med. 2009.

Tang S, Zhang R, Jiang F, Wang J, Chen M, Peng D, et al. Circulating irisin levels are associated with lipid and uric acid metabolism in a Chinese population. Clinical and Experimental Pharmacology and Physiology. 2015;: p. 896-901.

Sanchis-Gomar F, Alis R, Pareja-Galeano H, Sola E, Victor V, Rocha M, et al. Circulating irisin levels are not correlated with BMI, age,and other biological parameters in obese and diabetic patients. Endocrine. 2014;: p. 674-677.

Zhang C, Ding Z, Lv G, Li J, Zhou P, Zhang J. Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis. Journal of Diabetes. 2016;: p. 56-62.

Duran I, Gülçelik N, Ünal M, Topçuoğlu C, Sezer S, Tuna M, et al. Irisin levels in the progression of diabetes in sedentary women. Clinical Biochemistry. 2015; 48: p. 1268-72.

Kuzmicki M, Telejko B, Lipinska D, Pliszka J, Szamatowicz M, Wilk J, et al. Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol. 2014; 30: p. 636-9.

Yuksel M, Oncul M, Tuten A, Imamoglu M, Acikgoz A, Kucur M, et al. Maternal serum and fetal cord blood irisin levels in gestacional diabetes mellitus. Diabetes Res Clin Pract. 2014 April;: p. 171-175.

Hu H, Sun W, Yu S, Hong X, Qian W, Tang B, et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care. 2014;: p. 2718–22.

Wrann C, White J, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013 November; 5(18): p. 649–659.
Published
2017-05-12
How to Cite
DE ALENCAR, Jaqueline Pinheiro et al. Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review. International Archives of Medicine, [S.l.], v. 10, may 2017. ISSN 1755-7682. Available at: <http://imedicalsociety.org/ojs/index.php/iam/article/view/2552>. Date accessed: 25 sep. 2017. doi: https://doi.org/10.3823/2441.
Section
Endocrinology